Major differences in the responses of primary human leukocyte subsets to IFN-beta.
about
Harnessing Mechanistic Knowledge on Beneficial Versus Deleterious IFN-I Effects to Design Innovative Immunotherapies Targeting Cytokine Activity to Specific Cell TypesInduction and function of type I and III interferon in response to viral infectionChronic exposure to type-I IFN under lymphopenic conditions alters CD4 T cell homeostasisStructural and dynamic determinants of type I interferon receptor assembly and their functional interpretation.STAT2 deficiency and susceptibility to viral illness in humansInterferon-beta induces distinct gene expression response patterns in human monocytes versus T cellsStructural basis of a unique interferon-β signaling axis mediated via the receptor IFNAR1Gene expression profiling of the response to interferon beta in Epstein-Barr-transformed and primary B cells of patients with multiple sclerosisAntiviral activity of baicalin against influenza virus H1N1-pdm09 is due to modulation of NS1-mediated cellular innate immune responses.Interferon induction and function at the mucosal surface.Interferon impedes an early step of hepatitis delta virus infection.Activated STING in a vascular and pulmonary syndromemiR-155 as a multiple sclerosis-relevant regulator of myeloid cell polarization.Baseline gene expression signatures in monocytes from multiple sclerosis patients treated with interferon-betaTransient oscillatory dynamics of interferon beta signaling in macrophagesInterferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patientsThe role of macrophage IL-10/innate IFN interplay during virus-induced asthma.Type 1 interferon induction of natural killer cell gamma interferon production for defense during lymphocytic choriomeningitis virus infectionThe role of cell type-specific responses in IFN-β therapy of multiple sclerosis.Naive antibody gene-segment frequencies are heritable and unaltered by chronic lymphocyte ablation.Intestinal intraepithelial lymphocyte activation promotes innate antiviral resistanceElevated type I interferon-like activity in a subset of multiple sclerosis patients: molecular basis and clinical relevance.Dendritic cell maturation, but not type I interferon exposure, restricts infection by HTLV-1, and viral transmission to T-cells.Synthekines are surrogate cytokine and growth factor agonists that compel signaling through non-natural receptor dimers.Physiological evidence for diversification of IFNα- and IFNβ-mediated response programs in different autoimmune diseasesChanging partners at the dance: Variations in STAT concentrations for shaping cytokine function and immune responses to viral infections.Partial MHC class II constructs inhibit MIF/CD74 binding and downstream effectsThe functions of signal transducers and activators of transcriptions 1 and 3 as cytokine-inducible proteins.The hematopoietic regulator, ELF-1, enhances the transcriptional response to Interferon-β of the OAS1 anti-viral gene.Decreased interferon-β induced STAT-4 activation in immune cells and clinical outcome in multiple sclerosis.The molecular basis for differential type I interferon signaling.Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis.Interferon-beta therapy in multiple sclerosis: the short-term and long-term effects on the patients' individual gene expression in peripheral blood.
P2860
Q21131160-52F42E6D-FBD0-4A95-A98B-3C57E9868A4EQ27010065-F1EADAA0-33DF-4B5D-AD18-50DF4E94DBFAQ27330100-4510E250-B67C-4792-9E8A-98E8154B88BEQ27687338-D6CC94B3-BE85-4A96-9761-531460362775Q28115608-FDC94612-1BD3-4C91-A6FA-56FE9446FDD5Q28486504-250941E9-33AD-468A-8164-DAE7A4E4706EQ28509674-4DAC46CC-6490-4A5B-8AAA-59ED3D329383Q28540781-2BAB3EF8-2954-4CD0-B5A0-4E04372C6330Q30358265-9DA748CF-968D-4B80-A05A-1C8D6A490B68Q30661545-61EE523D-8E02-41A3-9C8F-79BD73CE5EC0Q33979916-7088D7A1-AFA9-4BC4-8CBA-88EA593BF858Q34241214-69B488AC-5D08-47CB-9ABD-AAC28320C830Q34354883-B0E629CF-A688-499F-9751-971D4410E145Q34700070-7BC27B5D-023E-428C-A43D-EDBC004138D5Q34803273-7D6A4D16-A3B0-4AFA-A6D7-8543C57B009DQ35044537-C4F5F224-AFB7-4428-81E2-E0979784756BQ35046046-9F867B43-1EB1-44D3-92FC-66E89EF2439AQ35149011-D425DFF2-E7B0-4921-B602-C79134EBA4DAQ35621233-0A436787-BCBA-4BAA-87C7-5AC17B959BC5Q35647840-29674183-383D-41B7-9E05-EBBF5436A22AQ35775433-E48B9ED1-FA1F-4DD9-B3B3-473A65D6589EQ36298955-CD5CFD7F-1EC4-49E5-905E-8009D80C0890Q36352268-B5A0E36B-17B9-444F-ABE5-EE2039074CDFQ36370053-59FA0B75-0918-441C-9F9B-F45AAE240952Q36588160-0C26EC0E-916A-4D24-B0D8-11E7D4652A01Q36895423-9EDE8DBE-8832-4FA8-B966-CE7760C777ECQ37210758-98F9E102-24CC-4B9A-ADAD-D71A0518C1CEQ37821935-00486F61-F64C-4579-BC94-CEC0BA00AEEFQ38813940-1066A1A8-DBB4-4C71-BF9B-97852D5E9A01Q39130808-170FCF19-1458-40E8-9BBA-ECE1290E3233Q39176574-ED4267F4-D687-4FC7-B5E7-35F1C134364AQ39404622-DA435EF5-7449-4CA3-A17A-A6BA7C0C67F5Q51025796-735C28C5-99E6-4FDA-8EB1-03F432A6C418
P2860
Major differences in the responses of primary human leukocyte subsets to IFN-beta.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Major differences in the responses of primary human leukocyte subsets to IFN-beta.
@ast
Major differences in the responses of primary human leukocyte subsets to IFN-beta.
@en
type
label
Major differences in the responses of primary human leukocyte subsets to IFN-beta.
@ast
Major differences in the responses of primary human leukocyte subsets to IFN-beta.
@en
prefLabel
Major differences in the responses of primary human leukocyte subsets to IFN-beta.
@ast
Major differences in the responses of primary human leukocyte subsets to IFN-beta.
@en
P2093
P2860
P356
P1476
Major differences in the responses of primary human leukocyte subsets to IFN-beta
@en
P2093
Anette H H van Boxel-Dezaire
George R Stark
Joana A Zula
Richard M Ransohoff
P2860
P304
P356
10.4049/JIMMUNOL.0902314
P407
P577
2010-10-18T00:00:00Z